 MORRISVILLE, N.C., Dec. 02, 2020 GLOBE NEWSWIRE -- Syneos Health, Inc. Nasdaq: SYNH the Company or Syneos Health, the only fully integrated biopharmaceutical solutions organization combining a CRO Contract Research Organization and a CCO Contract Commercial Organization, today announced the pricing of the previously announced underwritten secondary offering by affiliates of Thomas H. Lee Partners, L.P. and Advent International Corporation of an aggregate of 6,000,000 shares of the Companys common stock the Offering at a price to the public of 61.90 per share. Syneos Health is not selling any shares and will not receive any proceeds from the proposed sale of the shares by the selling stockholders in the Offering. The Offering is expected to close on December 3, 2020, subject to customary closing conditions. 